AZN - AstraZeneca PLC
About AstraZeneca PLC (https://www.astrazeneca.com)
AstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris. AstraZeneca engages with primary and specialty care physicians worldwide, facilitating distribution through a robust network of representatives and local offices across the United Kingdom, continental Europe, the Americas, Asia, Africa, and Australasia. The firm actively drives innovation through strategic collaborations, partnering with entities such as Neurimmune AG for the development and commercialization of NI006, BenevolentAI for systemic lupus erythematosus drug discovery, Lunit for AI-powered digital pathology risk assessment in NSCLC, and Absci Corporation for AI-driven oncology target identification. Founded in 1992, the company was initially known as Zeneca Group PLC, subsequently rebranding to AstraZeneca PLC in April 1999, and maintains its headquarters in Cambridge, United Kingdom.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Pascal Claude Roland Soriot | Chief Executive Officer & Executive Director | 1959 | $8,183,139 USD |
| Aradhana Sarin | Chief Financial Officer & Executive Director | 1974 | $3,628,032 USD |
| David Fredrickson | Executive Vice-President of Oncology Haematology Business Unit | 1975 | – |
| Iskra Reic | Executive Vice President of International | – | – |
| Jeffrey Pott | CHRO, Chief Compliance Officer, General Counsel & Member of External Sustainability Advisory Board | – | – |
| Joris Silon | Head of Investor Relations | – | – |
| Lutz Jermutus | Head of Projects | – | – |
| Pam Cheng | EVP of Global opt. & IT, Chief Sust. Officer and Member of External Sust.Adv. Board | 1970 | – |
| Ruth March | Senior Vice President of Precision Medicine - R&D Oncology | – | – |
| Ruud Dobber | Executive Vice-President of BioPharmaceuticals Business Unit | – | – |
| Susan Mary Galbraith | Executive Vice President of Oncology R&D | 1966 | – |